Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Operating Expenses (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Operating Expenses data on record, last reported at $14.3 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 7.62% year-over-year to $14.3 million; the TTM value through Sep 2025 reached $51.4 million, down 34.82%, while the annual FY2024 figure was $69.5 million, 59.86% down from the prior year.
  • Operating Expenses reached $14.3 million in Q3 2025 per BTAI's latest filing, down from $16.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $53.1 million in Q4 2022 and bottomed at $10.3 million in Q1 2025.
  • Average Operating Expenses over 4 years is $29.6 million, with a median of $24.7 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: skyrocketed 63.29% in 2023, then crashed 68.12% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $53.1 million in 2022, then crashed by 61.89% to $20.2 million in 2023, then crashed by 46.37% to $10.9 million in 2024, then surged by 31.93% to $14.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $14.3 million in Q3 2025, $16.0 million in Q2 2025, and $10.3 million in Q1 2025.